Uniqure NV

Five biotech stocks featured on RTTNews have delivered substantial gains, with upcoming catalysts that could drive further upside. uniQure N.V. surged 186% since August 2025, driven by positive data for its Huntington's disease gene therapy AMT-130, and is on track to submit regulatory filings in the third quarter of 2026. CareDx Inc. gained 138% since June 2025 after a series of strong earnings reports, raised guidance, and the acquisition of Naveris, with the commercial launch of the NavDx liquid biopsy test as a key catalyst. Adaptive Biotechnologies Corp. rose 130% since May 2025, supported by growing adoption of its clonoSEQ MRD test and multiple guidance raises, with the planned separation of its Immune Medicine business as a potential catalyst. Enliven Therapeutics Inc. jumped 207% since November 2025 on positive Phase 1 data for its chronic myeloid leukemia drug ELVN-001, and expects to initiate a Phase 3 trial in the second half of 2026. Amylyx Pharmaceuticals Inc. climbed 217% since June 2025, with a pivotal Phase 3 data readout for its post-bariatric hypoglycemia drug Avexitide anticipated in the third quarter of 2026.

Barclays upgraded UniQure to Overweight from Equal Weight and raised its price target to $65 from $25, citing the planned Biologics License Application submission for Huntington’s disease in the third quarter as a significant positive catalyst. The firm increased its probability assessment for the program’s success and highlighted the potential for multibillion-dollar peak sales. Separately, UniQure announced preliminary six-month follow-up data from the low-dose group of its Phase I/IIa study of AMT-260 for refractory mesial temporal lobe epilepsy, with three of six patients experiencing notable seizure reductions and no serious adverse events reported.

Biotech exchange-traded funds have posted strong gains in the first half of 2026, led by a 17.9% rise in the State Street SPDR S&P Biotech ETF as of June 17, as the FDA signaled a more flexible approach toward approving treatments for serious diseases. The shift fueled a nearly 78% surge in UniQure shares after the agency allowed the company to refile its Huntington's disease gene therapy application using three-year clinical trial data, reversing an earlier position that Phase 1 and Phase 2 data would not support accelerated approval. The FDA also opened new approval pathways for Atara Biotherapeutics and Replimune, and released favorable briefing documents for Moderna's flu vaccine ahead of an advisory committee meeting. Other biotech ETFs have also benefited, with the ARK Genomic Revolution ETF up about 20%, the iShares Genomics Immunology and Healthcare ETF up 14.5%, the Virtus Biotech Clinical Trials ETF up 11.6%, and the Global X Genomics & Biotechnology ETF up 10% year-to-date. The more supportive regulatory environment, which follows leadership changes at the FDA, comes alongside continued M&A activity including Merck's acquisition of Terns Pharmaceuticals and Novartis' purchase of Avidity Biosciences.

uniQure reported initial six-month follow-up results from the first low-dose cohort of six patients in its phase I/IIa study of AMT-260, an investigational gene therapy for refractory mesial temporal lobe epilepsy. Three of the six patients experienced substantial reductions in disabling seizures during months four through six, with declines ranging from 79% to 100% compared with baseline, while the other three showed mixed outcomes ranging from a 33% reduction to a 36% increase. No treatment-related or procedure-related serious adverse events were reported, and all adverse events were mild to moderate, with headache being the most frequent. Enrollment is underway in a second cohort evaluating a higher dose of AMT-260, with completion expected by mid-2026, and updated data from the study are planned for the first half of 2027.

Shares of uniQure surged 78.4% on June 17 after the FDA agreed that three-year data from the phase I/II study of its gene therapy AMT-130 could serve as the primary basis for a biologics license application seeking accelerated approval for Huntington's disease. The stock gave back 3.9% on June 18. During a recent type B meeting, the agency indicated it would work expeditiously to align on a confirmatory study design before the anticipated BLA filing in the third quarter of 2026, including consideration of a concurrent standard-of-care control group instead of a sham-controlled design. The update relieves investors after a March 2026 setback, when the FDA said the same data compared with an external control group were insufficient to support a marketing application and recommended a prospective, randomized, double-blind, sham surgery-controlled study. AMT-130, which uses uniQure's miQURE platform to silence the huntingtin gene, has received the first-ever Regenerative Medicine Advanced Therapy designation for a Huntington's disease therapy, along with Breakthrough Therapy and Fast Track designations.

UniQure NV shares surged 81% on Wednesday after the FDA reversed course and accepted its Huntington's disease therapy data for an accelerated approval filing, a move flagged days earlier by unusual options activity. The stock jumped from a prior close of $26.99 to an intraday high of $48.88, closing in the high $47s, after the agency indicated AMT-130 data would support a filing, reversing a March decision that had sent shares from $25 to $9. The rally was preceded by weeks of institutional call buying, including a multi-million dollar order on June 9 across October 33 and 43 strikes, which a trader highlighted as a signal of smart-money positioning. The same catalyst-driven approach is now being applied to five other biotech names: Celcuity faces a July 17 FDA decision for gedatolisib in breast cancer, with major funds holding through a prior drawdown; Ionis has two PDUFA dates—June 30 for olezarsen and September for zilganersen—though insider selling of $57.8 million warrants caution; Celldex awaits Phase 3 barzolvolimab data in chronic spontaneous urticaria in Q4 next year, with a Phase 2 readout this summer, but rich options premiums keep it on watch; Travere already won approval for FILSPARI in FSGS in April and is now a commercial execution and takeout story with Overweight ratings from Citi and JPMorgan; and Replimune resubmitted its BLA for RP1 after a second Complete Response Letter, with FDA alignment on May 29, drawing Baker Bros and other funds, though it remains the lowest-conviction name on the board.

uniQure's modelled fair value estimate has increased from about US$39.05 to roughly US$52.56, a 35% jump driven by revised assumptions around its AMT-130 gene therapy for Huntington's disease. Several Wall Street firms, including Barclays, RBC Capital, Cantor Fitzgerald, Leerink, and Goldman Sachs, have raised price targets after the company announced plans to file a biologics license application in the third quarter, with Barclays and Cantor Fitzgerald upgrading the stock to Overweight. Analysts cite FDA feedback allowing three-year Phase 1/2 data as the primary basis for the application as a major positive that eases regulatory uncertainty, while Barclays highlights a potential US$3 billion-plus peak sales opportunity. Goldman Sachs, despite lifting its target to US$46 from US$14, maintains a Neutral rating and points to remaining execution risks around confirmatory study design and durability data. The fair value model now assumes long-term revenue growth of roughly 137.44%, up from about 122.84%, with the future price-to-earnings multiple adjusting to approximately 109.07 times.

ClearPoint Neuro shares rallied 26% in the last trading session to close at $16.81 on heavy volume. The surge was driven by investor optimism after partner uniQure announced a regulatory milestone for its Huntington's disease treatment candidate AMT-130, with three-year Phase I/II data potentially supporting a Biologics License Application for accelerated approval. ClearPoint Neuro is expected to report a quarterly loss of $0.27 per share on revenues of $13 million, up 41% year-over-year. The stock carries a Zacks Rank of 3, or Hold.

uniQure led a group of biotech gainers on Wednesday after the FDA softened its stance on the company’s investigational gene therapy AMT-130 for Huntington’s disease. The agency now considers the 3-year analysis from the Phase I/II study acceptable as the primary basis for a Biologics License Application for accelerated approval, reversing its earlier recommendation for a prospective, randomized, double-blind, sham-surgery-controlled study. uniQure intends to submit the BLA in the third quarter of 2026, and its shares closed at $48.16, up 78.44%. Other notable movers included Elicio Therapeutics, which rose 70.65% after reporting that three advanced pancreatic cancer patients in its Phase 2 AMPLIFY-7P study achieved complete responses following treatment with its vaccine ELI-002 7P and subsequent checkpoint inhibitor therapy. Lunai Bioworks gained 40.06% after its CEO outlined developments including a first revenue-generating U.S. government defense contract and the formation of the Pathfinder Consortium. ClearPoint Neuro climbed 26.01% on spillover optimism related to uniQure’s AMT-130, which is administered using ClearPoint’s navigation system. Polyrizon added 15.55% after the publication of a U.S. patent application for its nasal drug delivery technology, and Faeth Therapeutics rose 14.59% as it anticipates topline data from a Phase 2 trial of its lead candidate PIKTOR in advanced endometrial cancer in the second half of 2026.

Computers and biotechnology stocks led sector gains on Wednesday. Computers shares rose about 5.6% as a group, with AstroNova surging about 70.2% and Nano Dimension Ltd up about 9.8%. Biotechnology shares advanced about 4.5%, driven by uniQure's roughly 74.1% jump and REGENXBIO's approximately 22.5% increase.

Several biotechnology companies reported significant regulatory, clinical, and commercial developments this week. NeOnc Technologies Holdings received Investigational New Drug authorization from the Department of Health – Abu Dhabi for NEO212, its oral brain tumor therapy, marking the first international regulatory clearance for the program. uniQure announced that the FDA indicated its Phase I/II data could support a Biologics License Application for accelerated approval of AMT-130 in Huntington's disease, with submission planned for the third quarter of 2026. IceCure Medical reported a 70% increase in its active U.S. commercial install base for the ProSense breast cancer cryoablation platform since receiving FDA clearance in October 2025. ClearPoint Neuro expanded its brain drug delivery ambitions through a 10-year focused ultrasound development partnership with Sungkyunkwan University in South Korea.

UniQure shares surged 67.5% in premarket trading after the gene therapy developer said the U.S. Food and Drug Administration agreed that three-year data from its Phase I/II study of AMT-130 could serve as the primary basis for a Biologics License Application seeking accelerated approval for Huntington's disease. Aehr Test Systems jumped 11% after announcing a follow-on production order for a fully automated FOX-XP wafer-level burn-in system from a major silicon photonics customer, with delivery expected within six months. Genco Shipping & Trading rose 8% after Diana Shipping increased its acquisition proposal to $27.34 per share in cash and stock, representing a substantial premium. Snap shares remained under pressure following a 9.6% drop in the previous session after unveiling its standalone augmented reality glasses, with investors skeptical about the commercial prospects. Leidos Holdings slipped 1.3% after BofA Securities downgraded the defense contractor to Neutral from Buy and cut its price target to $125 from $200.